These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30975452)

  • 1. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
    Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
    Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
    Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
    Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
    Yang A; Cannataro VL; Townsend JP
    Eur Urol; 2020 Jan; 77(1):e24-e25. PubMed ID: 31474441
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
    Rao N; Starrett GJ; Piaskowski ML; Butler KE; Golubeva Y; Yan W; Lawrence SM; Dean M; Garcia-Closas M; Baris D; Johnson A; Schwenn M; Malats N; Real FX; Kogevinas M; Rothman N; Silverman DT; Dyrskjøt L; Buck CB; Koutros S; Prokunina-Olsson L
    Cancer Prev Res (Phila); 2023 Oct; 16(10):561-570. PubMed ID: 37477495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
    Tomlinson DC; Hurst CD; Knowles MA
    Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.
    Shi MJ; Meng XY; Chen CL; Dyrskjøt L; Radvanyi F; Prokunina-Olsson L; Bernard-Pierrot I
    Eur Urol; 2020 Jan; 77(1):e26-e27. PubMed ID: 31493961
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
    Caswell D; Swanton C
    Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
    Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
    J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
    van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
    Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.
    Bakkar AA; Allory Y; Iwatsubo Y; de Medina SG; Maille P; Khreich N; Riou A; Leroy K; Vordos D; Abbou CC; Andujar P; Billebaud T; Chammings S; Conso F; De La Taille A; Fontaine E; Gattegno B; Ravery V; Sibony M; Radvanyi F; Chopin DK; Pairon JC
    Mol Carcinog; 2010 Jan; 49(1):25-31. PubMed ID: 19722178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genomic and transcriptomic landscape of metastastic urothelial cancer.
    Loriot Y; Kamal M; Syx L; Nicolle R; Dupain C; Menssouri N; Duquesne I; Lavaud P; Nicotra C; Ngocamus M; Lacroix L; Tselikas L; Crehange G; Friboulet L; Castel-Ajgal Z; Neuzillet Y; Borcoman E; Beuzeboc P; Marret G; Gutman T; Wong J; Radvanyi F; Dureau S; Scoazec JY; Servant N; Allory Y; Besse B; Andre F; Le Tourneau C; Massard C; Bieche I
    Nat Commun; 2024 Oct; 15(1):8603. PubMed ID: 39366934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.
    Lindley RA; Hall NE
    Mutat Res; 2018 Jul; 810():33-38. PubMed ID: 29957488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.
    Lamy P; Nordentoft I; Birkenkamp-Demtröder K; Thomsen MB; Villesen P; Vang S; Hedegaard J; Borre M; Jensen JB; Høyer S; Pedersen JS; Ørntoft TF; Dyrskjøt L
    Cancer Res; 2016 Oct; 76(19):5894-5906. PubMed ID: 27488526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
    Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
    J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.